Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

Key facts

Sponsor

Austin Neuromuscular Center

Principal Investigator

Yessar Hussain, MD, MD

Austin Neuromuscular Center

Intervention

Pozelimab/Cemdisiran(combination_product)

Enrollment

10 enrolled

Eligibility

45-75 years · All sexes

Timeline

2024 – 2027

Study locations (1)

• Austin Neuromuscular Center, Austin, Texas, United States

Collaborators

Regeneron Pharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Inclusion body myositis

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONNANCT07072676
  The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
  LMU Klinikum
• RECRUITINGPHASE2NCT06536166
  Ruxolitinib Treatment in Inclusion Body Myositis
  Assistance Publique - Hôpitaux de Paris
• ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT06450886
  Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
  Abcuro, Inc.
• ACTIVE NOT RECRUITINGNCT06153108
  Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time
  University of Kansas Medical Center
• ACTIVE NOT RECRUITINGPHASE3NCT04789070
  Phase III Trial of Sirolimus in IBM
  University of Kansas Medical Center
• ACTIVE NOT RECRUITINGNCT05046821
  Sporadic Inclusion Body Myositis Natural History Study
  University of California, Irvine

See all trials for Inclusion body myositis →